Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN)
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
antibody drug conjugate BHV-1510 combined with Regeneron's anti-PD-1 therapy cemiplimab across multiple solid tumors. The data showed a high confirmed objective response rate at the selected dose and durable responses beyond six months, highlighting BHV-1510's potential relevance in combination immunotherapy for difficult-to-treat cancers. We'll now examine how this promising BHV-1510 and cemiplimab response profile could influence Biohaven's investment narrative despite recent share price weakness. Find companies with promising cash flow potential yet trading below their fair value To own Biohaven today, you really have to believe its broad neuroscience and immunology pipeline can eventually turn heavy R&D spending and ongoing losses into commercial products, despite zero revenue and very large annual earnings deficits. The new BHV-1510 plus cemiplimab data slots into that story as a potential new pillar in oncology, and it arguably sharpens the near term catalyst list, which
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Pharmaceutical Holding Company Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]Yahoo! Finance
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]Yahoo! Finance
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology CongressPR Newswire
- Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/10/25 - Beat
BHVN
Sec Filings
- 11/18/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- BHVN's page on the SEC website